CN109715143A - 片剂组合物 - Google Patents

片剂组合物 Download PDF

Info

Publication number
CN109715143A
CN109715143A CN201780054265.1A CN201780054265A CN109715143A CN 109715143 A CN109715143 A CN 109715143A CN 201780054265 A CN201780054265 A CN 201780054265A CN 109715143 A CN109715143 A CN 109715143A
Authority
CN
China
Prior art keywords
tablet
weight
base
amino
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780054265.1A
Other languages
English (en)
Chinese (zh)
Inventor
斯恩尼瓦斯·S·巴特
斯科特·伯恩赛德
达尔尚·帕瑞克
顾重晖
赛义德·阿尔塔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Celgene Corp
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Priority to CN202510669668.3A priority Critical patent/CN120501712A/zh
Publication of CN109715143A publication Critical patent/CN109715143A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780054265.1A 2016-09-07 2017-09-06 片剂组合物 Pending CN109715143A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510669668.3A CN120501712A (zh) 2016-09-07 2017-09-06 片剂组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384643P 2016-09-07 2016-09-07
US62/384,643 2016-09-07
US201762535162P 2017-07-20 2017-07-20
US62/535,162 2017-07-20
PCT/US2017/050202 WO2018048847A1 (en) 2016-09-07 2017-09-06 Tablet compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510669668.3A Division CN120501712A (zh) 2016-09-07 2017-09-06 片剂组合物

Publications (1)

Publication Number Publication Date
CN109715143A true CN109715143A (zh) 2019-05-03

Family

ID=59895401

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780054265.1A Pending CN109715143A (zh) 2016-09-07 2017-09-06 片剂组合物
CN202510669668.3A Pending CN120501712A (zh) 2016-09-07 2017-09-06 片剂组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510669668.3A Pending CN120501712A (zh) 2016-09-07 2017-09-06 片剂组合物

Country Status (16)

Country Link
US (3) US11389454B2 (cg-RX-API-DMAC7.html)
EP (1) EP3509570A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019529534A (cg-RX-API-DMAC7.html)
KR (1) KR102498693B1 (cg-RX-API-DMAC7.html)
CN (2) CN109715143A (cg-RX-API-DMAC7.html)
AU (1) AU2017324844B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004356A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036053A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000573A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019002092A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP19015828A (cg-RX-API-DMAC7.html)
IL (1) IL265126B2 (cg-RX-API-DMAC7.html)
MX (1) MX392941B (cg-RX-API-DMAC7.html)
SG (1) SG11201901873PA (cg-RX-API-DMAC7.html)
WO (1) WO2018048847A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901321B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008138A1 (zh) * 2022-07-07 2024-01-11 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的药物组合

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
US20220401450A1 (en) * 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160089374A1 (en) * 2014-09-29 2016-03-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105916507A (zh) * 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
EP1416919A1 (en) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
JP2013536231A (ja) * 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド (r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3302442B1 (en) * 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ, インコーポレイテッド 悪性腫瘍の治療のための併用療法
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105916507A (zh) * 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US20160089374A1 (en) * 2014-09-29 2016-03-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008138A1 (zh) * 2022-07-07 2024-01-11 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的药物组合

Also Published As

Publication number Publication date
IL265126A (cg-RX-API-DMAC7.html) 2019-04-30
JP2022191265A (ja) 2022-12-27
JP2019529534A (ja) 2019-10-17
BR112019004356A2 (pt) 2019-05-28
CO2019002092A2 (es) 2019-05-31
US11389454B2 (en) 2022-07-19
ZA201901321B (en) 2023-12-20
AU2017324844B2 (en) 2023-05-11
CL2019000573A1 (es) 2019-07-19
US20220323447A1 (en) 2022-10-13
IL265126B1 (en) 2023-08-01
KR102498693B1 (ko) 2023-02-10
KR20190045199A (ko) 2019-05-02
US20180064715A1 (en) 2018-03-08
ECSP19015828A (es) 2019-03-29
NZ751112A (en) 2024-03-22
CN120501712A (zh) 2025-08-19
CA3036053A1 (en) 2018-03-15
SG11201901873PA (en) 2019-03-28
EP3509570A1 (en) 2019-07-17
AU2017324844A1 (en) 2019-03-21
US20240335450A1 (en) 2024-10-10
WO2018048847A1 (en) 2018-03-15
IL265126B2 (en) 2023-12-01
MX392941B (es) 2025-03-24
JP7487270B2 (ja) 2024-05-20
MX2019002697A (es) 2019-10-04

Similar Documents

Publication Publication Date Title
JP7487270B2 (ja) 錠剤組成物
US11504361B2 (en) Pharmaceutical compositions of therapeutically active compounds
TWI662963B (zh) 布魯頓氏酪胺酸激酶抑制劑之結晶形式
CN109069410A (zh) 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
JP2022033783A (ja) ブルトン型チロシンキナーゼ阻害剤の溶媒和形態
CA2955747A1 (en) Novel formulations of a bruton's tyrosine kinase inhibitor
JP2018509458A (ja) ブルトン型チロシンキナーゼ阻害剤の共結晶
EP4058028B1 (en) Pediatric formulations for treatment of cancer
EA049168B1 (ru) Таблетка для лечения пролиферативного заболевания
US20250170132A1 (en) Salts and polymorphic forms of menin inhibitors and pharmaceutical compositions thereof
WO2021234532A1 (en) Pharmaceutical formulations and their preparations for treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221212

Address after: new jersey

Applicant after: CELGENE Corp.

Applicant after: LES LABORATOIRES SERVIER

Address before: new jersey

Applicant before: CELGENE Corp.

Applicant before: AGIOS PHARMACEUTICALS, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190503